Howard Hughes Medical Institute

Parallel Bio Expands Scientific Leadership and Advisors from GSK, MIT, and Stanford

Retrieved on: 
Thursday, January 19, 2023
Software, Research, Other Health, Pharmaceutical, Robotics, Technology, Infectious Diseases, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Health, Other Science, Rubius, Massachusetts Institute of Technology, Disease, Bio, Pittsburgh, Howard Hughes Medical Institute, University, Immunity, Therapy, Physics, Machine learning, Stanford University, Magenta, 3D, Parallel, AI, Biology, Organoid, MIT, Immune system, Artificial intelligence, Patient, Drug discovery, Intelligence, Engineering, Bachelor of Engineering, GSK, Pharmaceutical industry, Medicine

“Dwight, Darrell, and Nima are an impeccable trio that combine pharmaceutical industry know-how with cutting-edge scientific research,” said Robert DiFazio, co-founder and CEO of Parallel Bio.

Key Points: 
  • “Dwight, Darrell, and Nima are an impeccable trio that combine pharmaceutical industry know-how with cutting-edge scientific research,” said Robert DiFazio, co-founder and CEO of Parallel Bio.
  • “Parallel Bio melds my passion for drug discovery with a rare opportunity to be on the leading edge of curing disease through the immune system,” Morrow said.
  • As Parallel Bio’s first scientific advisors, Darrell Irvine and Nima Aghaeepour bring combined expertise in immunology, bioengineering and the clinical application of artificial intelligence to the company.
  • Aghaeepour focuses on artificial intelligence and machine learning at his Stanford lab and has deep expertise in creating models to predict immunity and immune response.

Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board

Retrieved on: 
Friday, January 13, 2023
Stanford University School of Medicine, Nobel Prize, Cell, Nobel Prize in Physiology or Medicine, SAB, Brain, Sanofi, University, Max Planck Institute for Experimental Medicine, Howard Hughes Medical Institute, Yale School of Medicine, Division, Biophysics, Regulation of tobacco by the U.S. Food and Drug Administration, School, Avram Goldstein, Stanford University, Research, Center for Drug Evaluation and Research, Food, Synapse, Neuron, Neurotransmission, University of California, San Francisco, United States Air Force Scientific Advisory Board, Pharmaceutical industry, Medical device, University of Texas Southwestern Medical Center, Physiology, Medicine, Neuroscience

Dr. Südhof's appointment further strengthens the company's scientific resources, in line with the commitment to develop unique therapies for individuals with neurodegenerative and neuropsychiatric disorders.

Key Points: 
  • Dr. Südhof's appointment further strengthens the company's scientific resources, in line with the commitment to develop unique therapies for individuals with neurodegenerative and neuropsychiatric disorders.
  • On joining the SAB, Dr. Südhof will support the Company's leadership in its oversight and scrutiny of the Company's research and clinical development strategies.
  • Commenting on the appointment, Dr. Guosong Liu, Chairman and CEO of Neurocentria, said: "I am delighted to welcome Tom to Neurocentria.
  • In 2008, Dr. Südhof moved to Stanford University and became the Avram Goldstein Professor in the School of Medicine.

REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS

Retrieved on: 
Monday, January 9, 2023
Physical chemistry, Oregon Manufacturing Innovation Center, GlaxoSmithKline, Talent management, Human Genome Sciences, Therapy, People's Office Building, Research, Business, Clarkson University, AAV, Heel, Howard Hughes Medical Institute, Novavax, Robert H. Smith (philanthropist), Growth, Neuroscience, Bryn Mawr College, HGS, M.B.A, Manufacturing operations, Genencor, University, Engineering, Genentech, History of the University of Maryland, College Park, Senior, College Park, Management, Biology

They have played critical roles in the evolution of REGENXBIO into a near-commercial stage company.

Key Points: 
  • They have played critical roles in the evolution of REGENXBIO into a near-commercial stage company.
  • These promotions reflect on their contributions to date and their ability to lead the organization as we enter the next phase of growth.
  • Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations, manufacturing, supply chain, research and engineering roles.
  • Prior to joining REGENXBIO, he served as the Regional Supply Chain Head for North America at GlaxoSmithKline plc ("GSK").

IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

Retrieved on: 
Wednesday, December 7, 2022
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Tao, Vall, Helen, Immune-mediated inflammatory diseases, Federalisation of the European Union, Ephraim, COVID-19, University of Barcelona, Natural killer T cell, Teaching hospital, Phosphorylation, Virus, Bristol Myers Squibb, Partnership, American Cancer Society, Inflammation, University, Hospital, University School, Machine learning, National academy, EFIS, MD, Signal transduction, Howard Hughes Medical Institute, Science, DNS, University of California, San Francisco, Faculty, Immunology, Homeostasis, Immune system, Microbiota, International Union of Immunological Societies, Patient, Immunotherapy, Research, Journal, Tyrosine, UCSF, IMID, Biomedical sciences, Long, DN Capital, Nicholas J. Pritzker, Pharmaceutical industry, Medical device, Biotechnology, Microbiology, Rheumatology

Members of the IMIDomics Immunology Advisory Board include:

Key Points: 
  • Members of the IMIDomics Immunology Advisory Board include:
    Andr Veillette, M.D.
  • Dr. Veillete is a member of the COVID-19 Vaccine Task Force and the Long COVID Task Force of the Government of Canada.
  • He serves on multiple academic and industry advisory boards and the Pfizer Board of Directors.
  • His research group studies Natural Killer cells, which recognize and eliminate cells that have become transformed or infected by viruses.

BIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS

Retrieved on: 
Monday, December 5, 2022
Bio-Techne, Nature, Howard Hughes Medical Institute, Drug discovery, Mitochondrion, Flow cytometry, Research, Janelia Research Campus, Microscope, Pharmaceutical industry

These novel probes enable the fluorescent labeling and tracking of mitochondria in live and fixed cells.

Key Points: 
  • These novel probes enable the fluorescent labeling and tracking of mitochondria in live and fixed cells.
  • Fluorescent probes that enable highly accurate, sensitive, specific and persistent labeling of mitochondria is critical for a range of demanding scientific and biomedical applications, including high-content screening, flow cytometry and super-resolution microscopy.
  • To enhance the capabilities of modern imaging platforms used to conduct these studies, two types of MitoBrilliant probes have been developed targeting specific applications.
  • MitoBrilliant Live probes enable longer-term, dynamic monitoring of the mitochondrial membrane potential in live cells.

Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million Series A to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform

Retrieved on: 
Thursday, November 17, 2022
Sequence, Research, Sickle Cell Anemia, a Molecular Disease, Gilead Sciences, Genetics, QBI, University, Chemistry, Mutation, Doctor of Philosophy, KRAS, Howard Hughes Medical Institute, Biotechnology, UCSF, Molecular oncology, Liquid, Norwest Venture Partners, Biomarker, Gladstone Institutes, Proteomics, Disease, Drug development, Ron Conway, Biological engineering, Pharmacology, University of California, San Francisco, Biogen, Map, Therapy, SSD, UCSF Helen Diller Family Comprehensive Cancer Center, HHMI, Drug discovery, Pharmaceutical industry, Medical imaging, Management, Rezo

SAN FRANCISCO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched today with $78 million from a Series A financing. The Series A financing was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV Angel, Liquid 2 Ventures, and Hawktail. Rezo’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) developed by Nevan Krogan, Ph.D., director of QBI and a co-founder and chief executive officer of Rezo. Chemistry pioneer and inventor of leading drugs targeting KRAS, Kevan Shokat, Ph.D., is also a co-founder as well as a professor at UCSF, and an investigator of the Howard Hughes Medical Institute (HHMI).

Key Points: 
  • The platform enables the rapid identification and study of disease-causing protein and genetic interactions, which would be difficult to discover using traditional, often siloed, scientific methods.
  • Rezos disease-specific maps are designed to pinpoint novel, druggable targets that can be attacked with a range of treatment modalities.
  • Rezo aims to rapidly advance a pipeline of therapies, initially focused in solid tumor oncology guided by mutation and allele-specific biomarkers.
  • The companys initial focus is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships.

4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics

Retrieved on: 
Wednesday, November 16, 2022
Varenicline, Chemogenetics, Ion channel, The New England Journal of Medicine, Cell, Howard Hughes Medical Institute, Therapy, Patient, Ion, Protein, Central nervous system, Disease, Drug development, Nature, FDA, Pharmaceutical industry, Lancet

4BIO Capital (4BIO) is an international venture capital firm focused on investing in advanced therapies, including genomic medicines and other emerging technologies, to unlock the treatments of the future.

Key Points: 
  • 4BIO Capital (4BIO) is an international venture capital firm focused on investing in advanced therapies, including genomic medicines and other emerging technologies, to unlock the treatments of the future.
  • Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
  • Based in New York City, Redpin Therapeutics is a privately held, preclinical stage gene therapy company developing a proprietary chemogenetics platform for targeted cell therapies to address currently intractable diseases of the central nervous system.
  • Redpin is building an innovative ion channel-based chemogenetics platform that introduces a new paradigm for tunable, targeted cell therapies.

Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio

Retrieved on: 
Wednesday, November 16, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, FDA, National Organization for Rare Disorders, Nervous system, Ophthalmology, Brain, Investment, Biotechnology, Entrepreneurship, Therapy, Hyperkinesia, Drug development, Epilepsy, Trigeminal neuralgia, Howard Hughes Medical Institute, Multimedia, Conditional sentence, NORD, Triangle Park (Quezon City), Death, Acquisition, Disease, Central nervous system, Neuron, Neurological disorder, Ion, Neurology, SUDEP, Silicon, Pain scale, Patient, Pharmaceutical industry, Kriyā

Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc. , a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.

Key Points: 
  • Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc. , a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.
  • The acquisition serves as the foundation for Kriyas neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).
  • Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy.
  • The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in metabolic disorders, neurology and ophthalmology.

InvisiShield Technologies Announces the Appointment of Warner C. Greene, M.D., Ph.D. as President and Chief Scientific Officer

Retrieved on: 
Wednesday, November 16, 2022
Health, Infectious Diseases, Health Technology, COVID-19, Pharmaceutical, Biotechnology, University of California, San Francisco, Gladstone Institutes, American Academy, Warner, Mouse, Nasal cavity, Association of American Physicians, Physician, Washington University School of Medicine, RSV, AIDS, Howard Hughes Medical Institute, Internal medicine, Stanford University, Duke University Hospital, Nick, National academy, Long COVID, Severe acute respiratory syndrome coronavirus 2, Doctor of Philosophy, Vaccination, National Cancer Institute, COVID, National Academy of Medicine, Immunology, Hospital, Research, Science, Senior advisor, Pharynx, Urinary tract infection, Person, Microbiology, UCSF, Massachusetts General Hospital, Viral load, Immunodeficiency, COVID-19, University, Infection, Harvard University, Risk, MD, Vaccine, Pharmaceutical industry, Virology, William Ewart Gladstone, Medicine, San Francisco Bay Area

InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses today announced the appointment of Warner C. Greene, M.D., Ph.D., as President and Chief Scientific Officer.

Key Points: 
  • InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses today announced the appointment of Warner C. Greene, M.D., Ph.D., as President and Chief Scientific Officer.
  • Like many of us at Gladstone, Warners lab rapidly pivoted to work on SARS-CoV-2 in 2020.
  • We are thrilled for Warner that he is now joining InvisiShield to lead an innovative approach to preventing the spread of COVID-19 and reducing the risk of long COVID.
  • My goal is to bring our intranasal preventive spray for SARS-CoV-2 to people faster, said Dr. Greene.

COVID-19 Virus Increases Risk for Other Infections by Disrupting Normal Mix of Gut Bacteria

Retrieved on: 
Tuesday, November 1, 2022
MPH, Hospital, Research, Infection, COVID-19, Department, Coronavirus, NYU Langone Health, National Institutes of Health, Howard Hughes Medical Institute, Man, Severe acute respiratory syndrome coronavirus 2, Schluter, Jan, Crohn's disease, Immune system, G.H. Raisoni Department of Microbiology and Biotechnology, Book of Judith, Jan Vilček, Vedanta, Cadwell, Nature Communications, Patient, New York University Grossman School of Medicine, Yale University, The Kenneth Rainin Foundation, Genetics, Risk, Physician, Bacteria, Disease, Woman, Yale School of Public Health, National, Crohn's & Colitis Foundation, Q-system (genetics), Yale school, AbbVie, Mouse, NYU, DP2, Public health, Vaccine, Antibiotics, Pharmaceutical industry, Dietary supplement, MD, Autoimmunity, Doctor of Philosophy, Medicine, Microbiology

However, researchers say, it has remained unclear until now which came first, the coronavirus infection disrupting the gut microbiome or an already weakened gut making the body more vulnerable to the virus.

Key Points: 
  • However, researchers say, it has remained unclear until now which came first, the coronavirus infection disrupting the gut microbiome or an already weakened gut making the body more vulnerable to the virus.
  • The new investigation also revealed that antibiotic-resistant species can escape into the bloodstream, putting patients at greater risk for life-threatening secondary infections.
  • These antibiotic-resistant bacteria found in the gut were also observed to have migrated into the bloodstream in 20% of patients.
  • If any bacteria group made up a majority of the bacteria living in the gut, they were considered dominant.